1. Generics Bulletin

Hikma Outlines Strategy For Coping With COVID-19 Demand

US Propofol Launch Addresses Shortage Amid Higher Injectables Demand Overall

 
• By Dave Wallace

As Hikma launches propofol vials in three presentations in the US to address a local shortage, CEO Siggi Olafsson explains how the company is more broadly keeping on top of the higher demand generated by the coronavirus pandemic.

Rocket
Launching propofol in the US will help to address COVID-19 demand • Source: Shutterstock

Hikma’s launch of propofol 20ml, 50ml and 100ml vials in the US to help address COVID-19 shortages forms part of the firm’s wider strategy to react quickly to demand spikes related to the coronavirus pandemic, as set out by CEO Siggi Olafsson in an exclusive interview with Generics Bulletin.

Announcing this week the launch of the three presentations of propofol injectable emulsion – following US Food and Drug Administration approval of the firm’s supplemental abbreviated new drug application – Hikma noted that the product was currently on the FDA’s shortages list “following a surge in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.